| 초록 |
Natural killer cells are critical to the innate immune system because of their rapid responses to cancer cells and virus-infection. In this study, we fabricate nanoparticles targeting NK cells as a platform of the target delivery system. Our goals are to reduce undesired systemic side effects and enhance therapeutic effectiveness through concentrating immune-activation compounds into NK cells. To establish proof of concept, f(ab’)2 fragment of NK cells targeting antibody is conjugated on the surface of NPs. To confirm the in vitro and in vivo binding ability of NPs to target cells, NPs fluorescently labeled are co-incubated with mouse splenocytes and injected via the i.v. injection. As a result, antibody-conjugated NPs binds to 80% of the NK cell population, whereas unconjugated NPs are not. This result demonstrates that antibody conjugated NPs can bind to NK cells with minimized non-specific binding and show their potential as a target delivery platform. |
